Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : LLY source : Www.globenewswire.com save search
89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors
Published: 2024-04-17 (Crawled : 20:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
|
| O: -1.81%
H: 0.0%
C: 0.0%
biotech
CARGO Therapeutics Names Kapil Dhingra, M.B.B.S., to Board of Directors
Published: 2024-04-15 (Crawled : 20:00) - globenewswire.com
CRGX | $19.1 -2.05% -1.72% 190K
|
|
| O: -1.76%
H: 6.0%
C: 2.35%
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: 0.09%
H: 0.0%
C: 0.0%
BDTX A | $5.3 -7.02% -7.65% 1.8M
|
Health Technology
|
| O: 0.57%
H: 2.86%
C: 2.48%
AUTL | $4.8 -0.83% -0.83% 1.2M
|
Health Technology
|
| O: 0.0%
H: 2.04%
C: -0.82%
therapeutics
Roche granted FDA Breakthrough Device Designation for blood test to support earlier Alzheimer's disease diagnosis
Published: 2024-04-11 (Crawled : 05:00) - globenewswire.com
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: 1.06%
H: 0.47%
C: -0.03%
fda device disease test granted blood designation for alzheimer's roche
Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors
Published: 2024-04-09 (Crawled : 20:00) - globenewswire.com
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: -0.71%
H: 0.0%
C: 0.0%
ORIC | $9.51 -2.56% -2.74% 590K
|
Health Technology
|
| O: -2.81%
H: 1.54%
C: -3.57%
NRIX 2 d | $14.44 2.56% 2.43% 1.5M
|
Health Technology
|
| O: 18.35%
H: 1.98%
C: -5.88%
therapeutics
IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer
Published: 2024-04-05 (Crawled : 12:30) - globenewswire.com
IOBT | $1.47 -2.0% 1.95% 180K
|
|
| O: -0.58%
H: 0.0%
C: -5.88%
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: -2.06%
H: 2.77%
C: 2.45%
biotech business
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status
Published: 2024-04-02 (Crawled : 05:00) - globenewswire.com
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: -2.79%
H: 1.32%
C: 1.18%
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
|
| O: -1.14%
H: 0.02%
C: -1.06%
HCM | $16.36 -0.55% -0.43% 190K
|
Health Technology
|
| O: 0.21%
H: 1.49%
C: -0.06%
treatment advanced china
Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results
Published: 2024-03-27 (Crawled : 20:00) - globenewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -100.0%
H: NaN%
C: Infinity%
ERAS | $1.79 -2.72% -2.51% 650K
|
|
| O: 17.48%
H: 6.94%
C: -14.88%
NVS | $92.57 -0.55% 0.27% 840K
|
Health Technology
|
| O: 0.52%
H: 0.0%
C: 0.0%
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: 0.28%
H: 1.71%
C: -0.3%
business year financial results
ProQR Announces Year End 2023 Operating and Financial Results
Published: 2024-03-13 (Crawled : 11:00) - globenewswire.com
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: 0.27%
H: 0.5%
C: 0.11%
PRQR | $1.86 -2.11% -2.15% 180K
|
Health Technology
|
| O: -1.46%
H: 21.78%
C: 15.35%
year financial results
Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss
Published: 2024-03-12 (Crawled : 12:00) - globenewswire.com
PFE A | $25.39 -0.12% 0.24% 31M
|
Health Technology
|
| O: -0.21%
H: 0.11%
C: -1.06%
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: 0.9%
H: 2.03%
C: 1.89%
VERU | $1.42 22.41% 18.31% 6.9M
|
Health Technology
|
| O: -0.53%
H: 2.22%
C: -3.59%
ALT | $6.89 -2.13% -2.03% 2.7M
|
Commercial Services
|
| O: 0.3%
H: 11.41%
C: 9.8%
medical program
Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update
Published: 2024-02-28 (Crawled : 21:00) - globenewswire.com
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: -0.6%
H: 0.45%
C: 0.08%
MRUS | $40.47 -1.41% -1.58% 240K
|
Health Technology
|
| O: 2.3%
H: 0.58%
C: -2.69%
INCY | $52.82 0.19% 0.19% 1.5M
|
Health Technology
|
| O: 0.38%
H: 0.0%
C: -3.07%
business year update financial results
Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
Published: 2024-02-27 (Crawled : 12:30) - globenewswire.com
VERV | $6.66 -1.19% -1.2% 1.2M
|
Professional, Scientific, and T...
|
| O: 5.89%
H: 15.96%
C: 14.72%
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: -2.2%
H: 2.39%
C: 1.34%
VRTX | News | $393.48 0.1% 0.1% 780K
|
Health Technology
|
| O: 0.15%
H: 0.66%
C: -0.74%
year pipeline therapeutics financial results
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
Published: 2024-02-27 (Crawled : 12:00) - globenewswire.com
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: -2.2%
H: 2.39%
C: 1.34%
ACRS | $1.23 0.4% 560K
|
Health Technology
|
| O: 2.48%
H: 10.48%
C: -3.23%
year update therapeutics financial results
ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024
Published: 2024-01-19 (Crawled : 12:00) - globenewswire.com
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: -0.15%
H: 1.16%
C: 0.99%
PRQR | $1.86 -2.11% -2.15% 180K
|
Health Technology
|
| O: 2.36%
H: 2.76%
C: -4.15%
presentation technology platform
AVEO Oncology Enrolls First Patient in Pivotal FIERCE-HN Clinical Trial to Evaluate Ficlatuzumab in Combination with ERBITUX® (cetuximab) in Patients with HPV-negative Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
Published: 2024-01-16 (Crawled : 12:30) - globenewswire.com
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: 0.15%
H: 0.59%
C: -1.45%
erbitux first cell trial
Mesa Laboratories Appoints Mark Capone to its Board of Directors
Published: 2024-01-08 (Crawled : 13:00) - globenewswire.com
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: 0.63%
H: 0.58%
C: 0.58%
DHR | $236.36 -1.27% 0.24% 4.3M
|
Health Technology
|
| O: -0.56%
H: 2.71%
C: 2.6%
MLAB | $99.62 -1.5% -1.09% 31K
|
Health Technology
|
| O: -0.03%
H: 3.71%
C: 3.69%
ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration
Published: 2024-01-05 (Crawled : 12:00) - globenewswire.com
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: -0.08%
H: 0.97%
C: 0.74%
PRQR | $1.86 -2.11% -2.15% 180K
|
Health Technology
|
| O: 1.5%
H: 1.48%
C: -0.25%
research collaboration trust
Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate Cancer
Published: 2023-12-18 (Crawled : 12:30) - globenewswire.com
PNT | $13.68 2.63% 0.15% 0
|
|
| O: -10.09%
H: 0.0%
C: 0.0%
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: 1.61%
H: 1.14%
C: 0.57%
LNTH | News | $62.33 1.38% 1.38% 1.1M
|
Health Technology
|
| O: -19.87%
H: 5.04%
C: -8.75%
positive cancer biopharma topline trial results
AC Immune’s Targeted Anti-pTau Active Immunotherapy for Alzheimer’s Disease Advances into Phase 2b Trial
Published: 2023-12-15 (Crawled : 12:30) - globenewswire.com
JNJ | News | $145.74 0.67% -0.18% 7M
|
Health Technology
|
| O: -0.39%
H: 0.0%
C: 0.0%
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: -4.44%
H: 0.0%
C: 0.0%
ACIU | $2.38 -1.65% 0.41% 370K
|
Health Technology
|
| O: -1.62%
H: 9.04%
C: 7.4%
disease active alzheimer’s immunotherapy trial
Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors
Published: 2023-12-14 (Crawled : 12:00) - globenewswire.com
JNJ | News | $145.74 0.67% -0.18% 7M
|
Health Technology
|
| O: 1.81%
H: 0.0%
C: 0.0%
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: 1.8%
H: 0.0%
C: 0.0%
BEAM | $24.31 0.08% 1.7M
|
Health Technology
|
| O: 3.61%
H: 3.21%
C: 1.67%
biotech therapeutics
HUTCHMED Announces Continued Inclusion of ELUNATE® (fruquintinib) and SULANDA® (surufatinib) in the National Reimbursement Drug List in China at Current Terms
Published: 2023-12-13 (Crawled : 05:00) - globenewswire.com
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: 0.32%
H: 0.0%
C: 0.0%
HCM | $16.36 -0.55% -0.43% 190K
|
Health Technology
|
| O: -2.54%
H: 3.89%
C: 3.41%
elunate drug china
Gainers vs Losers
| 59% | 41% |
Top 10 Gainers
AGBA | News | $1.03 157.5% 57.94% 120M
|
Finance
ZCMD | $1.45 5.84% 52.1% 2.3M
|
Commercial Services
ISPC | $0.421 97.65% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.5 45.65% 470K
|
OST | $0.509 23.81% 45.26% 90K
|
GDHG | $0.263 21.76% 40.66% 3.1M
|
XPON | News | $3.15 63.21% 37.74% 16M
|
TIRX | $0.8 65.02% 30.74% 58M
|
BNTC | News | $6.82 42.08% 30.64% 3.5M
|
Health Technology
TPET | $0.3279 -3.56% 28.48% 33M
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.